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Supplemental Information 
 
Supplemental Methods 
Principal Component Analysis 
After the quality control, for the 4,835 individuals remaining with 695,193 single nucleotide 
polymorphisms (SNPs), we applied the following further SNP pruning filters: a 10% minor allele 
frequency, 10-3 Hardy-Weinberg equilibrium deviation threshold, and all SNPs within a 1500 SNP 
window had to have r2 below 0.2  (window shift of 150 used). Thus a subset of 71,677 SNPs was 
selected for principal component analysis using EIGENSOFT version 3.0 (1). Three covariate vectors 
were obtained and a total of 356 individuals with non-European ancestry were removed (HapMap2 
data and the average difference in the probe intensities across SNPs were used). 
 
Bayesian Meta-Analysis 
The Bayesian related effects model assumes a multivariate normal distribution with zero 
mean and covariance matrix 2Rs  as the prior distribution for the genetic effects on the log-odds 
scale. In this study, we have used a value 0.2s =  for the standard deviation of the effect size (see 
(2) for a justification) and in the correlation matrix R  we have set the correlation between our data 
and the two replication data sets to 0.9375 and between the two replication data sets to 0.99. This 
reflects the fact that the phenotype definition is more similar between the replication data sets than 
between our data and the replication data sets. The Bayes factor between this related effects model 
and the null model (all effects are a priori equal to zero) can be approximated by the ratio of two 
multivariate normal densities, 
2( | 0, var )
( | 0, var )
f b mean R S
f b mean S
s= = +
= =
, 
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evaluated at the effect size estimates from the three studies (collected in vector b ) and where S  is 
the diagonal matrix whose elements are the squared standard errors of those effect size estimates.  
 
Polygenic Score Analysis 
As explained in the main text, we performed a polygenic score analysis using the SNPs 
associated with schizophrenia in the Psychiatric GWAS Consortium (PGC) study. The 19,434 SNPs 
that were chosen as proxies for some PGC SNPs (see the main text) were aligned by the allele 
frequencies. 
A logistic regression model regressing the case-control status on the three principal 
components covariates and the polygenic score had pseudo R2 of 0.166 (Nagelkerke’s pseudo R2) 
and 0.0984 (McFadden’s pseudo R2), whereas for the model without polygenic score the 
corresponding values were 0.124 (Nagelkerke’s) and 0.0723 (McFadden’s). Here we interpret these 
values by saying that the variance explained by the polygenic scores is 4.2% (Nagelkerke’s scale) or 
2.6% (McFadden’s scale). The P value for the polygenic score was 6 x 10-25.  
Similar analyses were run adding further covariates accounting for the seven centers 
involved in the study and the P value for polygenic score remained small (5 x 10-14). With the centers 
as covariates, the pseudo variances explained by the polygenic score were 1.7% (Nagelkerke’s 
pseudo R2) and 1.4% (McFadden’s pseudo R2). 
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Figure S1. Principal components analysis of discovery data. Plotted is the projection of the study 
individuals on to the first two principal components (PC) of genetic structure. Individuals are colored 
according to recruitment locations as given in legend. 
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Figure S2. This Manhattan plot shows the evidence for association at all autosomal single nucleotide polymorphisms that passed quality control. Red line 
indicates a P value of 5 x 10-8 and blue line 1 x 10-5. This analysis includes all samples passing quality control in our discovery study: 1,239 cases, 857 
unaffected relatives and 2,739 healthy controls. 
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Figure S3. Forest plot showing the evidence of association in the discovery and replication cohorts. The plots show the estimated odds ratio (OR) and the 
95% confidence interval at the three single nucleotide polymorphisms presented in Table 2 and Figure 3. Combined estimates use fixed effects meta-
analysis. PGC, Psychiatric GWAS Consortium. 
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Figure S4. Variance explained (McFadden’s pseudo R2) by the polygenic scores by P-value threshold. 
The variance explained is plotted by P value threshold applied to the discovery Psychiatric GWAS 
Consortium schizophrenia sample (3) from a logistic regression model whose only covariates are the 
3 principal components. The corresponding significance of the polygenic score at each threshold 
ranged between 4.0 x 10-11 and 5.7 x 10-25. SNPs, single nucleotide polymorphisms. 
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Table S1. Samples prior to quality control and centers where they were collected. 
Center 
Location 
Number of Samples  
Details of Centers Patients Relatives Controls Total (%) 
London 406 352 522 1280 (18.5) Institute of Psychiatry – King’s 
College London 
Holland 649 649 1300 2598 (37.5) GROUP Consortium (University of 
Amsterdam, University of 
Groningen, Maastricht University, 
University of Utrecht) 
Perth 376 205 194 775 (11.2) The University of Western Australia 
Santander - 
Pamplona 
309 1 323 633 (9.1) Universidad de Cantabria 
 
Edinburgh 48 0 48 96 (1.4) University of Edinburgh 
Heidelberg 32 17 47 96 (1.4) Heidelberg University 
Munich 0 0 1457 1457 (21.0) Ludwig-Maximilians-Universität 
München 
Total 1820 1224 3891 6935  
 
 
 
  
PEIC and WTCCC2 
8 
 
Table S2. Quality control and sample exclusions in the discovery cohort. 
 Clinical Group  
 Patients Relatives Controls Total % 
Passed quality control & genotyped 1239 857 2739 4835 69.7 
Genotyping failure 204 83 735 1022 14.7 
Excluded –  >2% SNPs missing 67 59 88 214 3.1 
Excluded – duplicate or monozygotic twin 29 19 22 70 1.0 
Excluded – heterozygosity 33 13 24 70 1.0 
Excluded –  ancestry 139 107 110 356 5.1 
Excluded – sex mismatch 22 9 26 57 0.8 
Excluded – clinical reasons 21 0 0 21 0.3 
Failed DNA quality control 66 77 147 290 4.2 
Total 1820 1224 3891 6935  
 
 
 
 
Table S3. Quality control and exclusions of SNPs. 
Quality Control of SNPs SNP Count % 
Chromosomes X, Y and mitochondrial DNA exclusions 38,895 4.2 
SNPs with Mendelian inheritance errors 26,858 2.9 
SNP excluded if > 5% of individuals failed genotyping 11,610 1.2 
SNP excluded if MAF <2% 145,097 15.6 
SNP excluded if HWE p value < 1 x 10-6 2,404 0.3 
SNPs excluded due to poor calling (manually inspected in Evoker) 9,499 1.0 
SNPs that passed all quality control filters 695,193 74.8 
Total 929,556  
HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism. 
 
 
  
PEIC and WTCCC2 
9 
 
Table S4. Replication of previously published loci for schizophrenia and/or bipolar disorder (sign 
tests). The table shows the number of previously reported loci showing an effect size in the same 
direction at the best tag single nucleotide polymorphism (SNP) in Table 1. The sign test is a one-
sided binomial test for an increase in the fraction of SNPs where the risk allele is the same. Results 
are shown for all SNPs (top) and thinned to remove SNPs within 100kb and to exclude the MHC 
regions (bottom). Figure 1 provides a plot of these data. * indicates SNPs associated with both 
schizophrenia and bipolar disorder. P values in bold are significant at the 5% level.  
 All SNPs 
Phenotype 
Loci with published 
evidence of 
association 
Loci with same 
risk allele in our 
sample (%) 
Binomial test P 
value for 
enrichment 
Schizophrenia only 24 19 (79%) 0.0033 
Bipolar disorder only 10 5 (50%) 0.623 
Schizophrenia & bipolar disorder * 10 6 (60%) 0.377 
Schizophrenia (including *)  34 25 (73%) 0.0045 
Bipolar disorder (including *)  20 11 (55%) 0.41 
 Thinned SNPs excluding MHC 
Schizophrenia only 17 13 (76%) 0.025 
Schizophrenia (including *) 27 19 (70%) 0.026 
Bipolar disorder (including *) 18 11 (61%) 0.24 
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